Riskpilot← Back to searchSign inGet full accessGlyProVac ApS
APSActiveCVR 39724758Rørhatten 4Manufacture of pharmaceutical preparations · NACE 2120Est. 20188 employees
Revenue 2025
DKK -2,1M
+269% vs 2024
EBITDA margin
276.6%
-70% vs 2024
Equity ratio
-17.9%
Financial strength
Net profit 2025
DKK -5,2M
-71% vs 2024
| Revenue | DKK -2,1M | +269% |
| EBITDA | DKK -5,9M | -70% |
| Net profit | DKK -5,2M | -71% |
| Total assets | DKK 4,6M | +6% |
| Equity | DKK -832K | -27% |
| Employees | 8 | — |
Legal name
GlyProVac ApS
CVR number
39724758
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
3. juli 2018
Share capital
DKK 155.104
Employees
8 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er udvikle, kommercialisere, fremstille og sælge bakterielle vacciner.
Address
Rørhatten 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 145 | 1.051 | 993 | 1.321 | -815 | -577 | -2.129 |
| Staff expenses | -1.307 | -1.872 | -1.724 | -2.181 | -2.294 | -2.894 | -3.760 |
| EBITDA | -1.161 | -821 | -731 | -860 | -3.109 | -3.471 | -5.889 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -10 | -12 | -12 |
| EBIT | -1.161 | -821 | -731 | -860 | -3.119 | -3.483 | -5.902 |
| Net financials | -14 | -87 | -195 | -206 | -277 | -379 | -361 |
| Profit before tax | -1.175 | -908 | -926 | -1.066 | -3.396 | -3.862 | -6.262 |
| Tax | -257 | -209 | -439 | -432 | -524 | -847 | -1.093 |
| Net profit | -918 | -699 | -487 | -633 | -2.872 | -3.015 | -5.169 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 2.594 | 3.713 | 9.529 | 12.232 | 5.513 | 4.391 | 4.634 |
| Equity | 1.371 | 672 | 2.435 | 4.977 | 852 | -654 | -832 |
| Long-term debt | 520 | 2.188 | 4.407 | 3.901 | 4.171 | 4.559 | 4.932 |
| Short-term debt | 558 | 508 | 2.127 | 2.525 | 490 | 485 | 534 |
| Total debt | 1.078 | 2.696 | 6.534 | 6.427 | 4.662 | 5.044 | 5.466 |
EBITDA margin
-588926600.0%
This company
15.8%
Market median
-3727383644% vs market
20192025
Equity ratio
-17.9%
This company
38.2%
Market median
-147% vs market
20192025
Return on equity
-516899900.0%
This company
18.4%
Market median
-2809238687% vs market
20192025
Net profit margin
-516899900.0%
This company
8.1%
Market median
-6381480347% vs market
20192025
Asset turnover
-0.46×
This company
1.12×
Market median
-141% vs market
20192025
Debt / equity
6.57×
This company
0.62×
Market median
-960% vs market
20192025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-03 – 2019-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AZ Management | Management | 2018 | — | — |
AB Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
GlycoPharma Holding ApS | Company | 33.3% | 33.3% | 2022 |
Rossi Finans ApS | Company | 10.0% | 10.0% | 2023 |
| Individual | 10.0% | 10.0% | 2023 | |
I/S Rødeledsvej | Company | 5.0% | 5.0% | 2022 |
Uddannelses- og Forskningsstyrelsen | Company | 10.0% | 10.0% | 2023 |
AR CONSULT ApS | Company | 5.0% | 5.0% | 2022 |
Marigold Innovation ApS | Company | 5.0% | 5.0% | 2020 |
SYDDANSK INNOVATION ApS | Company | 5.0% | 5.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GlyProVac ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ann Zahle Andersen | Management | 0 companies |
| Anders Boysen | Chief Executive Officer | 0 companies |
| Tommi Petteri Kainu | Chairman | 0 companies |
| Kirsten Winther | Board of Directors | 0 companies |
| Allan Rosetzsky | Board of Directors | 0 companies |
| Peter Smedegaard | Chairman | 0 companies |
| Willem Adriaan de Jongh | Board of Directors | 0 companies |